



Proteomics International

LABORATORIES LTD

ASX Release

18 September 2025

ASX code: PIQ

**Proteomics International completes certification for
Diagnostic Laboratory operations
ISO 15189 Certification granted covering clinical testing services**

- **ISO 15189 certification is a core milestone in the commercialisation and clinical use of Proteomics International's suite of precision diagnostic tests**
- **Affirms Proteomics International's position as one of the world's leading laboratories for proteomics and protein-based based testing services**
- **Provides a platform for Proteomics International to offer emerging precision diagnostic and specialist pathology tests in future**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce it has been granted ISO 15189 certification for its Australian laboratory operations. This medical testing certification represents a core milestone in the commercialisation and clinical use of the Company's suite of precision diagnostic tests.

This internationally recognised accreditation supports Proteomics International's national roll-out of its specialist laboratory developed tests in Australia, including PromarkerD (launched 20 August) and PromarkerEso (launched today) [see PIQ Annual Report ASX: 27 August].

The certification builds on and extends Proteomics International's existing ISO 17025, ISO 13485 and CLIA certifications, and affirms the Company's position as one of the world's leading laboratories for proteomics and protein-based based testing services.

These certifications ideally position Proteomics International to offer both its in-house developed tests, and to commercialise other third-party specialist tests that are emerging globally. As precision medicine starts to become a reality for patients, each path offers enticing potential new revenue streams for the Company.

Proteomics International Managing Director Dr Richard Lipscombe said, *"The clinical certification supports our strategic growth trajectory as we advance the commercialisation of our first-in-class diagnostic tests for diabetic kidney disease, esophageal cancer and endometriosis. This certification also cements Proteomics International's position as a leading innovator in precision diagnostics and provides a platform for us to offer more specialist pathology testing in future."*

ISO 15189 is the global standard specifically developed for medical laboratories, outlining the quality management and technical requirements needed to ensure accurate and dependable test results. Certification was granted by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA) following a comprehensive audit of Proteomics International's Western Australian laboratory facilities, systems, and processes.

Proteomics International has multiple assets in its pipeline of precision diagnostics and the Company believes each test represents a substantial commercial opportunity in the public health market. This certification validates the Company's commitment to delivering high-quality, reliable, and clinically valid diagnostic testing services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Matthew Wright
Media and Public Relations
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Proteomics International (Europe)
Plesmanweg 9, 7602 PD Almelo
The Netherlands
T: +31 85 40 11 173
E: Europe@PromarkerD.eu